Sansure Biotech Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	3,771	3,968	4,590	4,233	3,213	2,636
Trading Asset Securities	151.64	157.1	139.67	548.28	2,451	2,046
Cash & Short-Term Investments	3,923	4,125	4,730	4,782	5,664	4,683
Cash Growth	-12.88%	-12.78%	-1.09%	-15.57%	20.95%	11.70%
Accounts Receivable	682.43	629.62	560.69	692.26	1,298	807.66
Other Receivables	29.79	28.36	27.58	23.49	82.41	14.3
Receivables	712.21	657.98	588.27	715.75	1,381	821.95
Inventory	443.04	413.69	392.75	376.63	355.31	369.5
Other Current Assets	82.41	77.15	78.7	75.45	125.83	92.09
Total Current Assets	5,161	5,274	5,790	5,950	7,525	5,966
Property, Plant & Equipment	1,323	1,335	1,113	1,043	785.27	481.03
Long-Term Investments	1,501	1,315	1,096	974.33	657.43	513.23
Goodwill	798.39	798.39	7.66	7.66	-	-
Other Intangible Assets	486.4	497.4	334.67	283.28	79.12	45.55
Long-Term Deferred Tax Assets	83.6	85.83	69.28	73.82	69.62	25
Long-Term Deferred Charges	179.79	175.37	147.27	97.05	46.7	16.26
Other Long-Term Assets	73.37	45.68	47.04	25.16	10.19	43.08
Total Assets	9,607	9,527	8,604	8,454	9,174	7,090
Accounts Payable	352.59	364.79	225.78	271.14	586.26	188.82
Accrued Expenses	57.8	84.26	290.03	363.33	622.39	231.82
Short-Term Debt	110.16	93.51	9	9	-	-
Current Portion of Long-Term Debt	53.75	55.34	-	-	-	-
Current Portion of Leases	-	-	5.28	11.1	14.26	8.49
Current Income Taxes Payable	32.81	18.72	0.21	17.66	145.25	80.16
Current Unearned Revenue	47.13	46.88	64.55	32.81	53.11	78.64
Other Current Liabilities	556.41	542.51	159.94	214.12	150.45	76.01
Total Current Liabilities	1,211	1,206	754.8	919.15	1,572	663.93
Long-Term Debt	1,006	966.3	396.65	-	-	-
Long-Term Leases	11.1	12.17	11.92	18.21	13.6	6.41
Long-Term Unearned Revenue	60.53	62.94	39.88	32.49	30.53	25.68
Long-Term Deferred Tax Liabilities	89.3	89.16	54.75	59.45	19.04	13.01
Other Long-Term Liabilities	-	-	-	-	26.09	-
Total Liabilities	2,377	2,337	1,258	1,029	1,661	709.03
Common Stock	579.39	579.39	582.39	588.46	588.46	400
Additional Paid-In Capital	1,565	1,565	1,702	1,908	1,914	2,065
Retained Earnings	5,135	5,085	5,194	5,177	5,371	4,082
Treasury Stock	-143.23	-143.23	-274.29	-515.33	-392.6	-200.01
Comprehensive Income & Other	28.52	30.39	39.01	43.26	19.36	21.71
Total Common Equity	7,164	7,116	7,243	7,201	7,501	6,369
Minority Interest	65.52	73.98	102.56	223.64	12.16	12.43
Shareholders' Equity	7,230	7,190	7,346	7,425	7,513	6,381
Total Liabilities & Equity	9,607	9,527	8,604	8,454	9,174	7,090
Total Debt	1,181	1,127	422.85	38.31	27.86	14.9
Net Cash (Debt)	2,742	2,998	4,307	4,743	5,636	4,668
Net Cash Growth	-25.03%	-30.39%	-9.20%	-15.83%	20.74%	12.83%
Net Cash Per Share	4.59	5.12	7.35	8.09	9.63	7.93
Filing Date Shares Outstanding	621.74	601.16	573.72	573.52	578.69	592
Total Common Shares Outstanding	621.74	601.16	573.72	572.21	578.69	592
Working Capital	3,950	4,068	5,035	5,030	5,954	5,302
Book Value Per Share	11.52	11.84	12.62	12.59	12.96	10.76
Tangible Book Value	5,879	5,820	6,901	6,910	7,421	6,323
Tangible Book Value Per Share	9.46	9.68	12.03	12.08	12.82	10.68
Buildings	-	-	834.41	826.53	344.51	231.04
Machinery	-	-	607.96	436.62	322.65	270.13
Construction In Progress	-	-	3.58	4.59	267.76	110.45

Source: S&P Global Market Intelligence. Standard template. Financial Sources.